10-K: Pressure BioSciences, Inc. Reports Full Year 2023 Results, Shifts Focus to Ultra Shear Technology

Pressure BioSciences, Inc. reports a net loss of $35.2 million for 2023, while strategically shifting its focus to its Ultra Shear Technology platform.

Summary

• Pressure BioSciences, Inc. (PBIO) reported a net loss of $35.2 million for the year ended December 31, 2023, compared to a loss of $17.8 million in 2022.
• The company's revenue increased by 14% to $1.98 million in 2023, driven by a 60% increase in instrument sales, while consumable sales decreased by 19%.
• Operating loss increased to $9.5 million in 2023 from $4.9 million in 2022, primarily due to increased general and administrative costs.
• Interest expense rose to $15.6 million in 2023 from $10.4 million in 2022, due to an increase in common stock and warrants issued for interest.
• The company is shifting its primary focus from Pressure Cycling Technology (PCT) to its Ultra Shear Technology (UST) platform, which it believes has greater commercial potential.
• PBIO has a plan to continue operations, including controlling expenses and obtaining equity or debt financing, but there is substantial doubt about its ability to continue as a going concern.
• The company has a significant amount of debt, including $21.3 million in convertible notes outstanding, some of which are past due.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there is positive news regarding revenue growth and strategic shifts, the significant increase in net loss, operating loss, and interest expense, coupled with the going concern warning, creates a negative sentiment. The company's future is highly dependent on its ability to raise capital and successfully commercialize its UST platform.

Positives

• Instrument sales increased by 60% in 2023, indicating growing market acceptance of PBIO's technology.
• The company is focusing on the high-potential Ultra Shear Technology (UST) platform.
• PBIO has a significant installed base of PCT systems in research laboratories worldwide.
• The company has a strong intellectual property portfolio with 48 issued patents and 16 pending patents.
• The acquisition of Uncle Buds provides a direct-to-consumer sales channel for PBIO's products.

Negatives

• The company experienced a significant net loss of $35.2 million in 2023.
• Operating losses increased by 94% in 2023 compared to 2022.
• The company has a substantial amount of debt, including $21.3 million in convertible notes, some of which are past due.
• There is substantial doubt about the company's ability to continue as a going concern.
• Consumable sales decreased by 19% in 2023.
• BaroFold and UST contract services revenue decreased by 56% in 2023.
• General and administrative costs increased by 141% in 2023.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and a working capital deficit.
• The company may not be able to obtain additional financing on favorable terms, if at all.
• The company's revenue is dependent on market acceptance of its products, which is not guaranteed.
• The company's business could be adversely affected if it fails to maintain effective disclosure controls and internal control over financial reporting.
• The company has incurred substantial debt, which could impair its flexibility and access to capital.
• The company may not be able to compete successfully with other companies in the industry.
• The company's success is dependent on the continued service of its senior management.
• The company may not be successful in growing its international sales.
• The company's operating results are subject to quarterly variation.
• The company's instrumentation operates at high pressures and may be subject to certain regulations.
• The company may be unable to protect its patents and other proprietary technology.
• The company may infringe on the intellectual property rights of others.
• The company may be unable to adequately respond to rapid changes in technology.
• The company's share price could be volatile and its trading volume may fluctuate substantially.
• The company's common stock is subject to the penny stock rules of the SEC.
• The company faces risks related to the Novel Coronavirus (COVID-19) which could continue to significantly disrupt its operations.

Future Outlook

The company plans to commercialize UST in multiple market segments in 2024, dependent on raising at least $2 million in equity or debt capital. The company also plans to initiate a Lease and License Model for UltraShear equipment in 2025.

Management Comments

• Management has developed a plan to continue operations, including controlling expenses and obtaining equity or debt financing.
• Management believes that the commercial potential for its UST platform far exceeds the potential of the PCT and BaroFold platforms.

Industry Context

The company operates in the life sciences industry, focusing on sample preparation, biopharmaceutical manufacturing, and nanoemulsion technologies. The report highlights the growing markets for mass spectrometry, biopharmaceuticals, and nanoemulsions, which are key areas for PBIO's technologies.

Comparison to Industry Standards

• The report mentions that the mass spectrometry market size was $5.4 billion in 2022 and is forecasted to reach $9.8 billion in 2032, indicating a strong growth potential for PBIO's PCT and CP-based products in this area. Companies like Thermo Fisher Scientific, Agilent Technologies, and Waters Corporation are major players in this market.
• The global biopharmaceuticals market was valued at $407.8 billion in 2022 and is anticipated to grow to $788.4 billion by 2031, suggesting a significant opportunity for PBIO's BaroFold platform. Companies like Roche, Novartis, and Sanofi are major players in this market.
• The report notes that traditional methods of protein refolding are inefficient and costly, highlighting the potential advantage of PBIO's BaroFold technology. Competitors in this space include companies using chemical denaturants for protein refolding.
• The report also mentions that the UST platform has potential in various markets, including nutraceuticals, cosmeceuticals, food & beverages, pharmaceuticals, agrochemicals, and industrial products. Competitors in the high-pressure processing space include Avestin, Bee International, and Microfluidics.

Related Party Transactions

• The company has a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (TDI), a related party.
• The company received short-term non-convertible loans from related parties.
• The company has a lease agreement with Target Discovery Inc.

Stakeholder Impact

• Shareholders face the risk of substantial dilution due to the company's corporate financing practices.
• Shareholders may lose their entire investment if the company cannot continue as a going concern.
• Employees may be affected by potential cost reduction measures or changes in operations.
• Customers may be affected by potential delays in product supply or changes in service offerings.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to commercialize UST in multiple market segments in 2024.
• The company plans to initiate a Lease and License Model for UltraShear equipment in 2025.
• The company plans to expand its Sales and Marketing team following a capital raise.
• The company plans to continue to raise cash through debt and equity offerings.

Key Dates

Keywords

Ultra Shear Technology, Pressure Cycling Technology, BaroFold Technology, biopharmaceuticals, nanoemulsions, biomarker discovery, mass spectrometry, protein refolding, sample preparation, cannabis extracts, biotherapeutics, precision medicine, biopharmaceutical quality control, biomolecule extraction, agrochemicals, nutraceuticals, cosmeceuticals, food and beverage